Autonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium Presentation

Rhea-AI Summary

Autonomix Medical (NASDAQ: AMIX) announced that Clarke Wilkirson, PhD, will present new long-term clinical data on pain mitigation in pancreatic adenocarcinoma at the SSO 2026 Annual Meeting March 5-7 in Phoenix.

The oral podium presentation describes a long-term analysis of denervation using a minimally invasive transvascular RF energy-based ablation and its potential effects on pain control and quality of life.

Key Figures

Presentation length: 5-minute talk + 2-minute Q&A Net loss: $14.0 million Cash used in operations: $9.4 million +5 more

8 metrics

Presentation length 5-minute talk + 2-minute Q&A SSO 2026 podium session on pancreatic cancer pain mitigation

Net loss $14.0 million Nine months ended Dec 31, 2025 (10-Q filed Feb 11, 2026)

Cash used in operations $9.4 million Nine months ended Dec 31, 2025

Cash balance $9.9 million As of Dec 31, 2025, with going concern disclosure

Financing need $30–$36 million Estimated additional funding to reach first indication commercialization

Potential warrant proceeds $7.7 million If all Common Warrants are exercised in cash under S-3/424B3

PIPE proceeds $5.0 million November 2025 private placement gross proceeds

Equity facility size $15.0 million Lincoln Park equity purchase agreement disclosed in Nov 2025 10-Q

Market Reality Check

Price: $0.3710 Vol: Volume 78,453 is below 20...

low vol

$0.3710 Last Close

Volume Volume 78,453 is below 20-day average 252,212 (relative volume 0.31), suggesting a light reaction pre-event. low

Technical Shares at 0.371 are trading below the 1.09 200-day MA and 87.99% below the 52-week high.

Peers on Argus

Two medical device peers in momentum (PAVM, BMRA) are moving down (median change...

2 Down

Two medical device peers in momentum (PAVM, BMRA) are moving down (median change around -8.2%) without related news, pointing to broader sector pressure, but AMIX’s own direction is not specified here.

Historical Context

5 past events · Latest: Jan 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 28	Conference presentation	Positive	-0.1%	Final RF ablation pain mitigation data accepted for SIO 2026 presentation.
Jan 09	Clinical data update	Positive	+2.8%	PoC study subgroup data showed rapid, durable pain relief in pancreatic cancer.
Dec 30	Patent grant	Positive	+8.3%	European patent granted for precision cardiac neuromodulation platform technology.
Dec 23	Investor presentation	Positive	-7.0%	CEO outlined IP expansion and multi-indication platform strategy to investors.
Dec 18	Conference selection	Positive	+4.6%	ASCO GI 2026 poster accepted on long-term RF pain mitigation analysis.

Pattern Detected

Clinical and IP milestones have often seen positive price alignment, while some corporate or visibility updates have produced mixed or divergent reactions.

Recent Company History

Over the last few months, Autonomix has repeatedly highlighted its nerve-targeted RF ablation platform and pancreatic cancer pain program. Clinical data at ASCO GI showed rapid and durable pain relief, and multiple conference acceptances underscored growing scientific visibility. The company also expanded its IP portfolio with a European patent and communicated a broader multi-indication strategy. Price reactions to these events were mixed but skewed positive after major clinical or IP updates. Today’s SSO podium selection continues that pattern of external clinical validation and conference exposure.

Regulatory & Risk Context

Active S-3 Shelf · $7.7 million

Shelf Active

Active S-3 Shelf Registration 2025-11-26

$7.7 million registered capacity

An effective S-3 shelf dated Nov 26, 2025 registers 13,504,998 warrant-related resale shares. While resale proceeds go to the selling holder, Autonomix could receive up to $7.7 million if all Common Warrants are exercised in cash at $0.8607 per share, which would significantly increase the share count and may weigh on valuation if resales accelerate.

Market Pulse Summary

This announcement adds another peer-reviewed platform for Autonomix’s pancreatic cancer pain program...

Analysis

This announcement adds another peer-reviewed platform for Autonomix’s pancreatic cancer pain program, advancing exposure beyond earlier ASCO GI and SIO presentations. The SSO 2026 podium slot underscores continued interest in its transvascular RF denervation approach. Against this, filings highlight a net loss of $14.0 million, cash of $9.9 million, and going concern risk, with an estimated $30–$36 million financing need. Investors may watch future data readouts, financing terms, and use of the $7.7 million warrant capacity.

Key Terms

pancreatic adenocarcinoma, denervation, transvascular, rf energy-based ablation, +1 more

5 terms

pancreatic adenocarcinoma medical

"Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation..."

Pancreatic adenocarcinoma is a type of cancer that starts in the cells of the pancreas, the organ that helps digestion and controls blood sugar. It matters to investors because it is often aggressive and hard to detect early, so progress or setbacks in diagnostics, drugs or clinical trials can strongly affect the value of companies working on treatments—similar to how a breakthrough or failure in fixing a critical bridge can change the fortunes of contractors and insurers.

denervation medical

"A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation"

Denervation is the loss or deliberate interruption of nerve signals to a specific organ or tissue, often achieved by cutting, destroying, or blocking nerves. Like unplugging a lamp to stop it from turning on, denervation is used as a medical approach to reduce unwanted activity such as high blood pressure or chronic pain; for investors it matters because devices and drugs that perform or affect denervation can drive clinical outcomes, regulatory decisions, safety profiles, and market opportunities.

transvascular medical

"denervation via Transvascular RF Energy-Based Ablation"

Transvascular describes medical procedures, devices or approaches that are performed through the body's blood vessels rather than by open surgery. Think of it like threading a tiny tool through plumbing to reach a problem inside, which often means smaller incisions, faster recovery and different regulatory and reimbursement pathways. Investors watch transvascular products because they can change clinical practice, drive demand for specialized devices and affect approval, adoption and reimbursement risk for healthcare companies.

rf energy-based ablation medical

"denervation via Transvascular RF Energy-Based Ablation"

A medical procedure that uses controlled radiofrequency (RF) electrical energy to heat and destroy targeted tissue, such as tumors, abnormal heart pathways, or nerves causing pain. Investors care because RF ablation devices, disposable probes, and related services drive sales, regulatory review, and reimbursement decisions; adoption rates and clinical outcomes influence demand much like how a more effective tool can replace older equipment in a workshop.

chronic pain medical

"Chronic pain is one of the most challenging complications faced by patients..."

Chronic pain is persistent or recurring pain that lasts weeks to years beyond the normal healing time, affecting daily function and quality of life. For investors, it matters because chronic pain drives long-term demand for medicines, devices, therapy services and care management, creating steady revenue streams, influencing regulatory approvals and reimbursement decisions, and shaping market size and risk for companies developing lasting treatments.

AI-generated analysis. Not financial advice.

THE WOODLANDS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Clarke Wilkirson, PhD, Clinical Development Engineer II, will present new long-term clinical data at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, happening March 5-7, 2026, in Phoenix, Arizona.

The presentation, titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation” (Submission ID: 2249416), has been accepted as an oral podium presentation. Dr. Wilkirson will deliver a five-minute presentation followed by a two-minute question-and-answer session, highlighting the potential of Autonomix Medical’s minimally invasive transvascular RF energy-based approach to address chronic pain in pancreatic cancer patients.

“Chronic pain is one of the most challenging complications faced by patients with pancreatic adenocarcinoma,” said Dr. Robert Schwartz, Co-Founder and Chief Medical Officer of Autonomix. “We are honored to share our long-term clinical analysis at SSO 2026, demonstrating how our transvascular RF approach may provide meaningful improvements in pain control and quality of life for patients facing this devastating disease.”

The SSO Annual Meeting convenes leading surgical oncologists, researchers and healthcare professionals to showcase advances in surgical oncology and emerging clinical technologies. For more information, please visit the conference website here.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact

JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com

FAQ

What will Autonomix Medical (AMIX) present at SSO 2026 on March 5-7?

Autonomix will present long-term clinical data on transvascular RF denervation for pancreatic cancer pain. According to Autonomix, the oral podium (Submission ID 2249416) covers a long-term analysis of denervation via a minimally invasive transvascular RF energy-based ablation and pain outcomes.

Who is presenting Autonomix Medical's (AMIX) data at the SSO 2026 Annual Meeting?

Clarke Wilkirson, PhD, Clinical Development Engineer II, will deliver the presentation. According to Autonomix, Dr. Wilkirson will give a five-minute oral podium talk followed by a two-minute Q&A at the SSO 2026 meeting in Phoenix.

What is the topic of Autonomix Medical's (AMIX) podium presentation at SSO 2026?

The presentation focuses on pain mitigation in pancreatic adenocarcinoma using transvascular RF energy-based ablation. According to Autonomix, it is a long-term analysis evaluating denervation and potential improvements in pain control and quality of life.

When and where will the Autonomix Medical (AMIX) podium presentation take place at SSO 2026?

The presentation is scheduled during the SSO 2026 Annual Meeting, March 5-7, 2026, in Phoenix, Arizona. According to Autonomix, the accepted oral podium session carries Submission ID 2249416 and includes a brief presentation plus Q&A.

How long is the Autonomix Medical (AMIX) podium presentation and Q&A at SSO 2026?

The session comprises a five-minute presentation followed by a two-minute question-and-answer period. According to Autonomix, this short oral slot will highlight key long-term clinical findings on transvascular RF denervation for pain mitigation.

What clinical outcomes does Autonomix Medical (AMIX) highlight in the SSO 2026 abstract?

Autonomix highlights potential improvements in pain control and patient quality of life from transvascular RF denervation. According to Autonomix, the long-term analysis suggests the minimally invasive approach may provide meaningful pain mitigation for pancreatic adenocarcinoma patients.